HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taking Stryker Forward: An Interview with Steve MacMillan

Executive Summary

A former pharmaceutical executive, Steve McMillan was tapped three years ago to replace John Brown as CEO of Stryker Corp. Following someone who had been in the post 30 years was daunting enough; even more so was continuing the record of strong financial performance that Stryker had maintained throughout its history. In this Interview adapted from the "From the Innovator's Workbench" series sponsored by Stanford University's BioDesign program, McMillan talks about the challenges he faced.

You may also be interested in...



Biomet Roars Back

Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.

Biomet Roars Back

Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.

Navigating Ortho's Choppy Seas: An Interview with Zimmer's David Dvorak

Since becoming CEO of orthopedics giant Zimmer two years ago, David Dvorak has faced a host of challenges unprecedented in this booming market, including a federal investigation into and settlement of questionable relationships with customers and the most severe economic crisis in 30 years. But Dvorak seems calm and confident as he looks ahead.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel